Failure to achieve complete resolution (combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
Ciclopirox probably leads to lower failure to achieve complete resolution (combined for face and scalp)… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life (health status) COPD Assessment Tool. Scale from 0 to 5; higher score indicates worse HRQoL Contains 10 questions with 5‐point Likert scale · individuals with stable bronchiectasis
The intervention showed no clear difference in health‐related quality of life (health status) COPD Assessment Tool.… (low certainty).
1 finding from 1 review
Intervention not reported
Cognitive function ‐ the Cognitive portion of the Alzheimer Disease Assessment Scale ADAS‐Cog1 · Huntington's disease
1 finding from 1 review
Intervention not reported
Cognitive function ‐ the Cognitive portion of the Vascular Alzheimer Disease Assessment Scale change V‐ADAS‐Cog1 · CADASIL
1 finding from 1 review
Intervention not reported
Activities of daily living ‐ Disability Assessment for Dementia scale DAD1 · CADASIL
1 finding from 1 review
Intervention not reported
Quality of life Investigator global assessment Scale from 1 to 7 · patients with essential tremor
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% leads to lower physician's assessment of global response of improvement, clear or… compared with tacrolimus 0.1% (high certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with pimecrolimus 1% (moderate certainty).
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa
Infliximab probably leads to higher physician global assessment compared with placebo (moderate certainty).
1 finding from 1 review
Participant global assessment VAS Visual analogue scale (VAS) (0 to 100 mm) · participants with hidradenitis suppurativa
1 finding from 1 review
Physician global assessment VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa
1 finding from 1 review
Participant global assessment VAS Scale from: 0 to 100 · participants with hidradenitis suppurativa
1 finding from 1 review
Participant global assessment: satisfaction with treatment Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light may leads to higher participant global assessment: satisfaction with treatment… compared with no treatment (low certainty).
1 finding from 1 review
Participant global assessment: satisfaction with treatment ‐ axilla Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light may leads to higher participant global assessment: satisfaction with treatment ‐ axilla… compared with no treatment (low certainty).
1 finding from 1 review
Participant global assessment: satisfaction with treatment ‐ groin Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light showed no clear difference in participant global assessment: satisfaction with treatment ‐ groin… compared with no treatment (low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Low